What's new? Log in Free sign up

Taysha Gene Therapies (TSHA) News and press releases

Company Profile

News

From Benzinga Pro

Taysha Gene Therapies Touts Encouraging Preclinical Data From Rett Syndrome Candidate

Biotech, News, Penny Stocks, Health Care, Movers, General

Taysha Gene Therapies Inc (NASDAQ: TSHA) presented preclinical data from neonatal mouse models on TSHA-102 for Rett syndrome, including new data in wild-type mice, at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting.

Taysha Gene Therapies Presents Preclinical Data On TSHA-102 For Rett Syndrome Demonstrating Cellular Regulation Of MeCP2 Expression In Key Mouse Models At The American Society Of Gene And Cell Therapy 26th Annual Meeting

Biotech, News, General

New preclinical data after neonatal administration in wild-type mice showed no detectable impact on survival, neurobehavioral functions and overall health, suggesting TSHA-102, engineered with novel miRARE technology,

FDA's Approval For Sarepta's Duchenne Gene Therapy, A Boost for Taysha Gene's Rare Neuropathy Treatment: Analyst Weighs

Analyst Color, Biotech, News, Penny Stocks, Health Care, Price Target, Analyst Ratings, Movers, Trading Ideas, General

On Friday, the FDA's adcomm voted 8 to 6 in support of accelerated approval of Sarepta Therapeutics Inc's SRPT SRP-9001 (delandistrogene moxeparvovec) for ambulatory patients with

Truist Securities Maintains Buy on Taysha Gene Therapies, Lowers Price Target to $2

News, Price Target, Analyst Ratings

Truist Securities analyst Joon Lee maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and lowers the price target from $3 to $2.

Analyst Ratings for Taysha Gene Therapies

Analyst Ratings

Needham Reiterates Buy on Taysha Gene Therapies, Maintains $6 Price Target

News, Price Target, Reiteration, Analyst Ratings

Needham analyst Gil Blum reiterates Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and maintains $6 price target.

Recap: Taysha Gene Therapies Q1 Earnings

Taysha Gene Therapies Q1 EPS $(0.28) Beats $(0.35) Estimate

Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.35) by 20 percent. This is a 78.63 percent increase over losses of $(1.31) per share

Earnings Scheduled For May 11, 2023

Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its first quarter.

Earnings Preview: Taysha Gene Therapies

Taysha Gene Therapies Announces Presentation On New Preclinical Data For TSHA-102 In Rett Syndrome At Upcoming American Society Of Gene And Cell Therapy 26th Annual Meeting

Biotech, News, Events, General

Taysha Gene Therapies, Inc. (NASDAQ:TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system

JMP Securities Reiterates Market Outperform on Taysha Gene Therapies, Maintains $4 Price Target

News, Price Target, Reiteration, Analyst Ratings

JMP Securities analyst Silvan Tuerkcan reiterates Taysha Gene Therapies (NASDAQ:TSHA) with a Market Outperform and maintains $4 price target.

Morgan Stanley Maintains Equal-Weight on Taysha Gene Therapies, Lowers Price Target to $1

News, Price Target, Analyst Ratings

Morgan Stanley analyst Michael Lapides maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Equal-Weight and lowers the price target from $3 to $1.

Cantor Fitzgerald Maintains Overweight on Taysha Gene Therapies, Lowers Price Target to $2

News, Price Target, Analyst Ratings

Cantor Fitzgerald analyst Kristen Kluska maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Overweight and lowers the price target from $13 to $2.

Chardan Capital Maintains Buy on Taysha Gene Therapies, Lowers Price Target to $5

News, Price Target, Analyst Ratings

Chardan Capital analyst Geulah Livshits maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and lowers the price target from $6 to $5.

Stocks That Hit 52-Week Lows On Wednesday

On Wednesday, 81 companies hit new 52-week lows.

Taysha Gene Therapies Q4 EPS $(0.99) Misses $(0.33) Estimate, Sales $2.50M Miss $8.18M Estimate

Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.99) per share which missed the analyst consensus estimate of $(0.33) by 200 percent. This is a 25 percent increase over losses of $(1.32) per share

Earnings Scheduled For March 28, 2023

Companies Reporting Before The Bell • Futu Holdings (NASDAQ:FUTU) is expected to report quarterly earnings at $0.70 per share on revenue of $237.12 million.

Taysha Gene Therapies's Earnings: A Preview

Stocks That Hit 52-Week Lows On Friday

On Friday, 469 companies hit new 52-week lows.

Press releases

From Benzinga Pro

Taysha Gene Therapies Presents Preclinical Data on TSHA-102 for Rett Syndrome Demonstrating Cellular Regulation of MeCP2 Expression in Key Mouse Models at the American Society of Gene and Cell Therapy 26th Annual Meeting

Health Care, Press Releases

New preclinical data after neonatal administration in wild-type mice showed no detectable impact on survival, neurobehavioral functions and overall health, suggesting TSHA-102, engineered with novel miRARE technology,

Taysha Gene Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update

Earnings, Press Releases

Screening completed and dosing scheduled for first potential subject in the Phase 1/2 REVEAL trial in Rett syndrome; dosing of first adult patient with TSHA-102 expected in Q2 2023; initial available Phase 1/2 clinical

Taysha Gene Therapies Announces Presentation on New Preclinical Data for TSHA-102 in Rett Syndrome at Upcoming American Society of Gene and Cell Therapy 26th Annual Meeting

News, Health Care, Press Releases

DALLAS, April 27, 2023 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of

Taysha Gene Therapies Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Earnings, Press Releases

Initiated screening of first potential subject in Phase 1/2 REVEAL trial in Rett syndrome; dosing of first adult patient with TSHA-102 expected in H1 2023; submitted protocol amendment to allow for younger patients;

Taysha Gene Therapies to Release Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call and Webcast on March 28

DALLAS, March 15, 2023 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.